Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHE:002399)
China flag China · Delayed Price · Currency is CNY
9.83
-0.06 (-0.61%)
Sep 4, 2026, 3:04 PM CST

SHE:002399 Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Income
202.53349.49646.74-783.26727.43240.79
Depreciation & Amortization
369.81354.57331.05361.23307.66302.74
Other Amortization
18.6528.8710.2216.6110.544.64
Loss (Gain) From Sale of Assets
-0.53-1.84-0.721.682.765.1
Asset Writedown & Restructuring Costs
14.11105.07-75.62112.670.421.1
Loss (Gain) From Sale of Investments
68.7116.13-110.426.35175.2226.82
Loss (Gain) on Equity Investments
---447.95--
Provision & Write-off of Bad Debts
11.8417.9828.55-48.8671.85
Other Operating Activities
100.57160.63160.98-126.46283.59267.7
Change in Accounts Receivable
405.83-132.51-25.38316.89-176.1141.77
Change in Inventory
558.46914.211,245189.8-2,152-1,520
Change in Accounts Payable
-230.81-143.67-63.43-125.2159.71423.9
Change in Unearned Revenue
----68.29--
Change in Other Net Operating Assets
---48.25-1.46-2.24
Operating Cash Flow
1,4791,7132,194398.22-756.61-6.63
Operating Cash Flow Growth
-24.10%-21.93%450.99%---

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Capital Expenditures
-79.46-121.1-202.77-437.43-222.42-193.86
Sale of Property, Plant & Equipment
1.372.173.012.342.531.72
Divestitures
30.69.9----
Sale (Purchase) of Intangibles
----7.45--
Investment in Securities
-1,019-824.92-545.211,565336.53323.36
Other Investing Activities
150.3861.2329.9199.36133.2588.71
Investing Cash Flow
-915.72-872.75-415.051,222249.84719.93

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Long-Term Debt Issued
-2,4282,6875,1096,7563,694
Long-Term Debt Repaid
--3,092-4,691-6,033-6,162-3,767
Lease Payments
-25.2-42.91-38.21-37.98-38.33-36
Net Debt Issued (Repaid)
-299.77-663.76-2,005-923.29594.15-72.79
Common Dividends Paid
-620.97-430.81-159.9-176.21-251.01-412.48
Other Financing Activities
-13.76-24.81-110.68-13.58-15.81
Financing Cash Flow
-934.5-1,095-2,140-1,210329.56-501.08

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Foreign Exchange Rate Adjustments
-21.3321.0416.8336.3317.28-62.83
Net Cash Flow
-392.87-233.32-343.82445.94-159.93149.39

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
1,3991,5921,991-39.22-979.03-200.49
Free Cash Flow Growth
-20.12%-20.06%----
Free Cash Flow Margin
26.70%29.05%37.71%-0.72%-13.68%-3.15%
Free Cash Flow Per Share
0.951.081.36-0.03-0.67-0.14
Levered Free Cash Flow
849.581,3401,632183.13-1,494-435.43
Unlevered Free Cash Flow
863.661,3851,720322.64-1,347-309.41
Free Cash Flow After Leases
1,3741,5491,953-77.2-1,017-236.49

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash Interest Paid
---249.83--
Cash Income Tax Paid
343.92145.99247.7362.14-270.8-129.34
Change in Working Capital
693.01582.061,203361.44-2,313-1,127